• In the past quarter, Acadia Healthcare Company, Inc. reported second-quarter 2026 results showing sales of US$865.84 million and net income of US$10.93 million, alongside weaker earnings per share than a year earlier.
• Despite softer quarterly profitability, management raised full-year 2026 revenue guidance to US$3.40–US$3.45 billion, highlighting confidence in the company’s underlying demand and growth pipeline.
• Next, we’ll examine how Acadia’s weaker quarterly earnings but higher full-year revenue guidance affect the existing investment narrative for the business.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Acadia Healthcare Company Investment Narrative Recap

To be a shareholder in Acadia, you need to believe that demand for behavioral healthcare and improved payer mix can ultimately translate into stronger, more consistent earnings, despite today’s weak profitability. This quarter’s softer EPS does not materially change that bigger picture, but it does keep execution risk in focus, especially around managing underperforming facilities and start up losses, which remain the key near term swing factors for both margins and investor confidence.

The most relevant update here is management’s decision to slightly raise full year 2026 revenue guidance to US$3.40–US$3.45 billion, even as net income and EPS declined year over year. That combination suggests the nearer term catalyst remains tied to whether higher volumes and pricing can eventually offset cost pressures and operational drags, rather than any immediate change from capital allocation moves such as the paused buyback activity in recent quarters.

Yet against that stronger revenue outlook, investors should still be aware of the risk that ongoing legal and regulatory investigations could...

Acadia Healthcare Company's narrative projects $3.9 billion revenue and $189.9 million earnings by 2029. This requires 4.9% yearly revenue growth and about a $1.3 billion earnings increase from -$1.1 billion today.

Uncover how Acadia Healthcare Company's forecasts yield a $32.21 fair value, in line with its current price.

Exploring Other Perspectives

The lowest analyst estimates paint a much more cautious picture, assuming revenue of about US$3.8 billion and earnings near US$227 million by 2029, so if you are weighing that view against recent guidance and ongoing regulatory scrutiny, it is worth exploring how far apart these expectations really are.

Explore 4 other fair value estimates on Acadia Healthcare Company - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Acadia Healthcare Company research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Acadia Healthcare Company research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Acadia Healthcare Company's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 51 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.